Cost-effectiveness of lung transplantation and its evolution: the Portuguese case
- 397 Downloads
We analyzed the costs and outcomes of lung transplant in Portugal and its evolution since it was first performed in 2000.
Data were collected for all patients waiting for transplant from 31 December 2000 until 31 December 2010 (n = 61). Patients waiting for transplant were used as the comparison group. We calculated the mean restricted survival time using the Kaplan–Meier estimation method. The time horizon was closed upon the death of the last surviving patient. Costs and consequences were discounted at 5 % per annum. We calculated the incremental cost-effectiveness ratio of transplant as compared to no transplant. Deterministic and probabilistic sensitivity analyses were performed. We tested volume-outcome effects using a parametric survival regression.
The cost of lung transplantation was 77,223€ per QALY and 121,276€ per life-year. Assuming a 50,000€/QALY willingness-to-pay, lung transplant would be cost-effective with a 37 % probability. Survival improved substantially from 5.15 years over the 2001–2010 period to 6.94 years for the 2008–2010 period. When restricting our analysis to the 2008–2010 period, the cost-effectiveness ratio decreased to €79,016 per life-year gained and €69,241 per QALY. Survival was significantly associated with the number of procedures performed.
Although above commonly accepted cost-effectiveness thresholds, the economic value of lung transplant holds promise in Portugal due to the large improvement in survival over the 2001–2010 period. The life-threatening character of the motivating conditions, the absence of alternative treatment, and equity concerns should be also accounted for when assessing the “value for money” of lung transplant.
KeywordsCost-effectiveness Health technology assessment Lung transplantation Volume-outcome Portugal
JEL ClassificationI12 D61 H51
- 1.Christie, J.D., Edwards, L.B., Kucheryavaya, A.Y., Benden, C., Dipchand, A.I., Dobbels, F., Kirk, R., Rahmel, A.O., Stehlik, J., Hertz, M.I.: International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J. Heart Lung Transpl. 31(10), 1073–1086 (2012)CrossRefGoogle Scholar
- 3.Neymark, N., Adriaenssen, I., Gorlia, T., Caleo, S., Bolla, M.: Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 11(3), 233–248 (2002)PubMedCrossRefGoogle Scholar
- 6.Administração Central do Sistema de Saúde (ACSS, Central Administration of the Health System): Base de Dados dos Elementos Analíticos. Ministério da Saúde, Administração Central do Sistema de Saúde (2013). http://www.acss.min-saude.pt/bdea/, last Accessed 3rd May 2013
- 7.Diário da República: Portaria 839-A/2009. Portugal (2009)Google Scholar
- 8.Infarmed [National Authority of Medicines and Health Products, IP]: Estatística do Medicamento 2008 [Drug Statistics 2008], Ministry of Health, Lisbon (2008)Google Scholar
- 9.Pordata. Base de Dados Portugal Contemporâneo [Database Contemporary Portugal]. http://www.pordata.pt/Portugal/Ambiente+de+Consulta/Tabela, last Accessed 3rd May 2013
- 10.Silva, E.A., Pinto, C.G., Sampaio, C., Pereira, J.A., Drummond, M., Trindade, R.: Orientações metodológicas para estudos de avaliação económica de medicamentos. Infarmed, Ministry of Health, Lisbon (1998)Google Scholar
- 11.Andronis, L., Barton, P., Bryan, S.: Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Prepress Projects (2009)Google Scholar
- 12.Latimer, N.: NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation With Patient-Level Data. Report by the Decision Support Unit. School of Health and Related Research. University of Sheffield, UK (2013)Google Scholar
- 13.Organization for Economic Cooperation and Development. OECD.StatExtracts. http://stats.oecd.org/Index.aspx?DataSetCode=CPL, last seen on 5th April 2013Google Scholar
- 14.XE Currency converter, http://www.xe.com/currencyconverter/, last seen on 5th April 2013
- 17.NICE guide to the methods of health technology appraisal. London: NICE (2013)Google Scholar
- 18.National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. January 2009. http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf, last Accessed 28th May (2013)